---
schema_version: "secwatch.filing_event.v1"
accession: "0000886163-26-000054"
form_type: "8-K"
ticker: "LGND"
cik: "0000886163"
company_name: "LIGAND PHARMACEUTICALS INC"
filed_at: "2026-09-24T11:15:07+00:00"
generated_at: "2026-09-24T11:35:29.882200+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Ligand invests up to $47M in AvenCell for royalty on CAR-T pipeline

## Summary
- Ligand commits $41M for mid single-digit to low double-digit royalty on worldwide net sales of AvenCell pipeline assets, including AVC-201 and AVC-203.
- Funding in four tranches; first at closing, rest on clinical milestones and financing conditions.
- Ligand also commits up to $6M in AvenCell Series C financing.
- AvenCell's lead candidate AVC-201 is in Ph1b for relapsed/refractory AML; AVC-203 in Ph1a for B-cell malignancies.

## SEC filing metadata
- accession: 0000886163-26-000054
- form_type: 8-K
- ticker: LGND
- cik: 0000886163
- company_name: LIGAND PHARMACEUTICALS INC
- filed_at: 2026-09-24T11:15:07+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/886163/000088616326000054/0000886163-26-000054-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/886163/000088616326000054/lgnd-20260924.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000886163-26-000054
- JSON: https://secwatch.observer/filing/0000886163-26-000054.json
- Plain text: https://secwatch.observer/filing/0000886163-26-000054.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.